drugset / Trial / NCT01732692

Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

NCT01732692

Phase 3 Completed 140 enrolled Takeda Norgine · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare colon cleansing quality induced by the 2 different modes of MOVIPREP® intake in 5 colon segments prior to colonoscopy.

Timeline

Start
2012-11
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Moviprep Other / unclassified 2000 ml

Indications

No indication recorded.